AstraZeneca (AZ) has agreed to acquire CinCor Pharma (CinCor) – a company which concentrates on developing novel treatments for hypertension and chronic kidney disease.
The addition of the company will increase AZ’s cardiorenal pipeline as it will include CinCor’s candidate drug, baxdrostat.
Baxdrostat is a selective, oral small molecule inhibitor of aldosterone synthase – the enzyme responsible for the synthesis of aldosterone in the adrenal gland – and can be used for blood pressure lowering in treatment-resistant hypertension.
The drug represents a potentially leading next-generation aldosterone synthase inhibitor as it is selective for aldosterone synthase and, critically, spares the cortisol pathway among humans.
There is also potential for combining baxdrostat with Farxiga – a move which upholds AZ’s strategy to provide benefits throughout cardiorenal diseases, especially where there is a high unmet medical need.
Marc de Garidel, chief executive officer of CinCor, reflected: “We are excited about the proposed acquisition of CinCor by AZ as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”
He added: “CinCor is committed to ensuring a smooth transition of the development responsibilities to AZ a once the acquisition is consummated.”
Mene Pangalos, executive vice president BioPharmaceuticals R&D, AZ, concluded: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.
“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”
by John Pinching
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.